TAK-448
- Generic Name
- TAK-448
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C58H80N16O14
- CAS Number
- 1234319-68-6
- Unique Ingredient Identifier
- YO029HR229
- Background
TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.
- Associated Conditions
- -
- Associated Therapies
- -
Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 17
- Registration Number
- NCT02381288
A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT02369796
Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01132404
- Locations
- 🇫🇷
Hôpital Edouard Herriot, 5, Place d'Arsonval, Pavillon V - Urologie et chirurgie de la transplantation, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath